美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

百濟神州

299.94

-5.8000-1.90%

盤後：299.940.00000.00%17:04 EDT

成交量：47.30萬

成交額：1.43億

市值：355.88億

市盈率：-80.99

高：306.58

開：302.89

低：298.46

收：305.74

資料載入中...

總覽公司新聞公告

單國洪即將加入百濟神州向吳曉濱彙報

南方财经网

百濟神州6月30日成交額為9745.38萬美元

中金：維持百濟神州(06160)“跑贏行業”評級目標價198港元

中國創新藥5個月對外授權455億美元，百濟神州澤布替尼全球銷售13億美元！

中國創新藥能否持續讓世界買單？券商分析師最新觀點

百濟神州：開創性腫瘤平臺行業標準制定者

中国国际金融股...

8家藥企去年人均薪酬超過50萬，包括百濟神州、迪哲醫藥等

百濟神州的“創新超級乘法”

Ofweek维科网

BGB-43395：在既往三線治療的乳腺癌及實體瘤患者具初步療效和良好安全性

百濟神州的新時代

百濟神州6月27日成交額為9694.06萬美元

百濟神州研發日：未來 18 個月，預計將迎來 20 項里程碑進展

Insight数据库

百濟神州的醫保猜想：領先外企一個身位，還有必要談嗎？

叮噹健康旗下藥房上架百濟神州注射用澤尼達妥單抗(百赫安)

國產創新藥破曉時刻！華安醫藥軍團以科技思維定義投資新範式

港股生物醫藥股延續回調，百濟神州跌超8%

老虎资讯综合

6 月，恆瑞、百濟神州、復星醫藥等新藥又有新進展，多個關鍵 III 期臨牀啓動

Insight数据库

解讀全球製藥企業50強榜單：中國創新藥企距離“Big Pharma”還有多遠

每日经济新闻

百濟神州在研發日展示開創性腫瘤治療管線

醫藥估值重估邏輯

资本市场那些事儿

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ONC/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百濟神州","latestPrice":299.94,"timestamp":1753905600000,"preClose":305.74,"halted":0,"volume":473024,"hourTrading":{"tag":"盘后","latestPrice":299.94,"preClose":299.94,"latestTime":"17:04 EDT","volume":1443,"amount":433016.27,"timestamp":1753909481311},"delay":0,"floatShares":75541600,"shares":118650120,"eps":-3.70325,"marketStatus":"未開盤","change":-5.8,"latestTime":"07-30 16:00:00 EDT","open":302.89,"high":306.58,"low":298.46,"amount":142842075.17312,"amplitude":0.026559,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1753948800000},"marketStatusCode":0,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":305.74,"preHourTrading":{"tag":"盘前","latestPrice":302.03,"preClose":305.74,"latestTime":"09:26 EDT","volume":20145,"amount":6149166.5685,"timestamp":1753882010837},"postHourTrading":{"tag":"盘后","latestPrice":299.94,"preClose":299.94,"latestTime":"17:04 EDT","volume":1443,"amount":433016.27,"timestamp":1753909481311},"volumeRatio":1.182299,"impliedVol":0.4534,"impliedVolPercentile":0.7133},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75541600,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":1.182299,"shares":118650120,"dividePrice":0,"high":306.58,"amplitude":0.026559,"preClose":305.74,"low":298.46,"week52Low":155.75,"pbRate":"10.17","psRate":"8.52","week52High":308.87,"institutionHeld":0,"latestPrice":299.94,"eps":-3.70325,"divideRate":0,"volume":473024,"delay":0,"ttmEps":-3.70325,"open":302.89,"prevYearClose":184.71,"prevWeekClose":291.47,"prevMonthClose":242.07,"prevQuarterClose":242.07,"fiveDayClose":294.83,"twentyDayClose":245.16,"sixtyDayClose":255.77,"earningDate":1756483200000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548022919","title":"單國洪即將加入百濟神州 向吳曉濱彙報","url":"https://stock-news.laohu8.com/highlight/detail?id=2548022919","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548022919?lang=zh_tw&edition=fundamental","pubTime":"2025-07-01 14:13","pubTimestamp":1751350433,"startTime":"0","endTime":"0","summary":"南方财经7月1日电，原武田制药全球高级副总裁、武田中国总裁单国洪(SeanShan)将于2025年8月18日加入百济神州，出任大中华区、中亚和南亚区域总经理，并向吴晓滨汇报。单国洪将主导百济神州在大中华区、中亚和南亚这一关键增长区域的运营与战略发展，同时还将推进构建高效协同的区域运营模式，最大程度响应患者需求，助力公司全球化战略的深入实施。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507013445012475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","BK1161","BK1588","LU2328871848.SGD","LU0307460666.USD","BK4526","LU0588546209.SGD","BK1500","BK4139","BK1583","LU1969619763.USD","06160","02197"],"gpt_icon":0},{"id":"2548026060","title":"百濟神州6月30日成交額為9745.38萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548026060","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548026060?lang=zh_tw&edition=fundamental","pubTime":"2025-07-01 12:14","pubTimestamp":1751343249,"startTime":"0","endTime":"0","summary":"美东时间2025年6月30日，百济神州成交额为9745.38万美元，成交额较昨日增加0.53%，当日成交量为40.21万股。百济神州于2025年6月30日涨0.36%，报242.07美元，该股过去5个交易日跌6.0%，年初至今涨31.05%，过去60日跌11.9%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701121416a4c80ca2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701121416a4c80ca2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","ONC"],"gpt_icon":0},{"id":"2548042228","title":"中金：維持百濟神州(06160)“跑贏行業”評級 目標價198港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548042228","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548042228?lang=zh_tw&edition=fundamental","pubTime":"2025-07-01 09:19","pubTimestamp":1751332770,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持百济神州2025年和2026年盈利预测不变。该行维持跑赢行业评级，基于DCF模型，该行维持A/H/US股目标价280元/198港元/332美元。6月26日，公司在投资者研发日活动中，展示了独特的研发战略、领先的血液瘤布局、以及广泛的实体瘤管线。公司继续沿用了百悦泽的成功开发经验，多管线并行创新，唯优质分子推向临床，这也是这些新分子在临床前就展示了BIC潜力的原因之一。另外IRAK4 CDAC半衰期优秀，计划于2H25启动II期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1312457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","06160","688235"],"gpt_icon":0},{"id":"2548104668","title":"中國創新藥5個月對外授權455億美元，百濟神州澤布替尼全球銷售13億美元！","url":"https://stock-news.laohu8.com/highlight/detail?id=2548104668","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548104668?lang=zh_tw&edition=fundamental","pubTime":"2025-07-01 06:53","pubTimestamp":1751324002,"startTime":"0","endTime":"0","summary":"2025年前五个月，国内创新药企对外授权交易总金额已达455亿美元，超越2024年上半年交易总额。百济神州缔造了中国药企首个十亿美元重磅药泽布替尼，该药于2019年在美国FDA首次获批上市，2023年全球销售额达13亿美元。2024年百济神州实现收入38亿美元，核心产品泽布替尼贡献收入26亿美元，推动公司亏损额持续收窄。这一突破标志着中国创新药在全球医药创新格局中地位的提升。商业化成果显著中国创新药企业对外授权交易金额屡创新高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/01065351396453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1500","06160","BK1161","BK0239","BK4139","BK1574","LU0307460666.USD","159992","LU1969619763.USD","LU0588546209.SGD","LU2328871848.SGD","06978","ONC","688235","BK1588","BK4526"],"gpt_icon":0},{"id":"2547015164","title":"中國創新藥能否持續讓世界買單？券商分析師最新觀點","url":"https://stock-news.laohu8.com/highlight/detail?id=2547015164","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547015164?lang=zh_tw&edition=fundamental","pubTime":"2025-06-30 23:29","pubTimestamp":1751297340,"startTime":"0","endTime":"0","summary":"医药魔方统计，2025年1—5月，中国创新药企对外授权交易总金额已达455亿美元，超过2024年上半年的交易总额，创新药出海授权交易大爆发。亮眼数据的背后，是中国创新药整体水平的强势崛起。“中国创新药产业的研发、临床与生产能力，正处于与国际一线水平接轨的初始阶段。”由于BD数据不及预期，年内大涨明显的创新药企业荣昌生物股价近期大幅回调，从而带动创新药板块整体调整。华泰柏瑞恒生创新药ETF6月中旬以来一度单周下行超过8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630233154a7267585&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630233154a7267585&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603259","603567","06160","688131","601089","688181","688222","600056","600062","600196","600351","600420","688166","600216","603456","603998","159992","603707","688091","600422","688202","600513","688520","688278","688336","600276","ONC","603229","688136","600079","600521","600789","688073","600774","688331","601607","688513","688356","600998","688235","603716","603087","600682","600721","BK0239","600572","603367","600557","603590","600332","600851","600267","688319","600200","600867","688117","600535","688488","688506","688163","600645","605199","688177","688505","688321","688068","688317","688189","603127","600881","600080","688198","600380","600222"],"gpt_icon":0},{"id":"2547096481","title":"百濟神州：開創性腫瘤平臺 行業標準制定者","url":"https://stock-news.laohu8.com/highlight/detail?id=2547096481","media":"中国国际金融股...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547096481?lang=zh_tw&edition=fundamental","pubTime":"2025-06-30 19:48","pubTimestamp":1751284087,"startTime":"0","endTime":"0","summary":"公司近况6 月26 日，公司在投资者研发日活动中，展示了独特的研发战略、领先的血液瘤布局、以及广泛的实体瘤管线。公司继续沿用了百悦泽的成功开发经验，多管线并行创新，唯优质分子推向临床，这也是这些新分子在临床前就展示了BIC潜力的原因之一。另外IRAK4 CDAC半衰期优秀，计划于2H25 启动II期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063019481197948d97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063019481197948d97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","ONC","688235","BK4139","06160"],"gpt_icon":0},{"id":"2547531310","title":"8家藥企去年人均薪酬超過50萬，包括百濟神州、迪哲醫藥等","url":"https://stock-news.laohu8.com/highlight/detail?id=2547531310","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547531310?lang=zh_tw&edition=fundamental","pubTime":"2025-06-30 12:07","pubTimestamp":1751256420,"startTime":"0","endTime":"0","summary":"根据2024年财报，8家药企人均薪酬超过50万元，其中百济神州以90.48万元位居榜首，员工人数达1.1万人。百济神州不仅在血液学领域有显著进展，还在实体瘤领域拓展了多元管线。迪哲医药人均薪酬68.67万元，其两款产品舒沃替尼和戈利昔替尼已在中国获批上市，并带动公司营收大幅增长。亚虹医药、益方生物、盟科药业、艾力斯、福瑞股份、诺诚健华的人均薪酬分别为62.74万元、61.91万元、56.4万元、55.36万元、53.66万元、52.82万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063012131297941cff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063012131297941cff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","688235","ONC","BK4139","688192"],"gpt_icon":0},{"id":"2547740039","title":"百濟神州的“創新超級乘法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2547740039","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547740039?lang=zh_tw&edition=fundamental","pubTime":"2025-06-30 09:27","pubTimestamp":1751246828,"startTime":"0","endTime":"0","summary":"百济神州的研发效率极高。着眼未来，百济神州仍计划保持这种快速验证的势头。这种管线的广度、深度及推进速度，无疑是其“创新超级乘法”最直观的体现。巩固血液瘤基本盘的同时，百济神州进军高发实体瘤领域，布局多样化且差异化的新分子。“专注”之外，百济神州提升确定性的另一关键策略是积极拓展“联合疗法”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506300928009793f2a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506300928009793f2a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","BK1588","BK1161","ONC","BK1500","06160","LU2328871848.SGD","LU1969619763.USD","688235","BK1583","LU0307460666.USD"],"gpt_icon":0},{"id":"2547005844","title":"BGB-43395：在既往三線治療的乳腺癌及實體瘤患者具初步療效和良好安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=2547005844","media":"山西证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547005844?lang=zh_tw&edition=fundamental","pubTime":"2025-06-30 00:00","pubTimestamp":1751212800,"startTime":"0","endTime":"0","summary":"BGB-43395 是CDK4 的高度选择性抑制剂，靶向控制细胞分裂的检查点蛋白以阻止癌细胞生长。BGB-43395具有潜在同类最佳血液学安全性特征，在既往接受过多线治疗的CDK4/6 经治患者中临床治疗有效。BGB-43395 剂量优化后安全性良好，血液毒性发生率低。BGB-43395 与氟维司群联用在实体瘤患者中观察到初步抗肿瘤活性。BGB-43395+氟维司群剂量递增给药后，37 例可评价实体瘤患者的ORR 为15%，其中19 例可评价乳腺癌患者的ORR 为11%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630115118a72524a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630115118a72524a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK0239","ONC","688235"],"gpt_icon":0},{"id":"2547085826","title":"百濟神州的新時代","url":"https://stock-news.laohu8.com/highlight/detail?id=2547085826","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547085826?lang=zh_tw&edition=fundamental","pubTime":"2025-06-29 16:37","pubTimestamp":1751186273,"startTime":"0","endTime":"0","summary":"继首季度盈利之后，近日举办的投资者研发日活动让百济神州又一次站在聚光灯下。泽布替尼只是开始，百济神州血液瘤的上市产品格局即将焕新，新王牌索托克拉已在华申报上市，并预计在今年下半年推进全球申报。基于此，百济神州将在今年Q3开放乳腺癌和妇科恶性肿瘤的肿瘤特异性扩展队列，以进一步确认BG-C9074在B7-H4高表达肿瘤患者中的疗效和安全性。在肺癌领域，百济神州正在打造行业领先的产品组合。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250629164711a723c846&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250629164711a723c846&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","LU2328871848.SGD","BK1161","BK1588","ONC","BK1500","BK1583","LU0307460666.USD","06160","LU0588546209.SGD","688235"],"gpt_icon":0},{"id":"2546763867","title":"百濟神州6月27日成交額為9694.06萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546763867","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546763867?lang=zh_tw&edition=fundamental","pubTime":"2025-06-28 12:18","pubTimestamp":1751084322,"startTime":"0","endTime":"0","summary":"美东时间2025年6月27日，百济神州成交额为9694.06万美元，成交额较昨日减少9.17%，当日成交量为40.08万股。百济神州于2025年6月27日跌5.22%，报241.2美元，该股过去5个交易日跌2.38%，年初至今涨30.58%，过去60日跌11.01%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628121843a7220f4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628121843a7220f4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","ONC"],"gpt_icon":0},{"id":"2546772031","title":"百濟神州研發日：未來 18 個月，預計將迎來 20 項里程碑進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2546772031","media":"Insight数据库","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546772031?lang=zh_tw&edition=fundamental","pubTime":"2025-06-28 08:04","pubTimestamp":1751069069,"startTime":"0","endTime":"0","summary":"6 月 26 日，百济神州举行了投资者研发日活动。未来 18 个月内，预计将迎来 20 项里程碑进展。百济神州现拥有 1200+名科研人员，覆盖多样化的治疗模式。截至 5 月 28 日，百济正在进行临床开发的产品有 30 个，进行中的临床试验有 96 项。百济神州是唯一一家在 3 个 CLL 基础作用机制中均拥有潜在 BIC 产品的公司。预期里程碑事件展望未来 18 个月，百济神州将有望迎来多个关键后期催化剂和关键早期催化剂事件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628081518a721bdba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628081518a721bdba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160","688235","BK0239"],"gpt_icon":0},{"id":"2546774624","title":"百濟神州的醫保猜想：領先外企一個身位，還有必要談嗎？","url":"https://stock-news.laohu8.com/highlight/detail?id=2546774624","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546774624?lang=zh_tw&edition=fundamental","pubTime":"2025-06-27 20:46","pubTimestamp":1751028396,"startTime":"0","endTime":"0","summary":"5月29日，百济神州HER2靶点的重磅新药泽尼达妥单抗正式获批上市，用于治疗既往接受过全身治疗的HER2高表达不可切除局部晚期或转移性胆道癌患者。泽尼达妥单抗成为全球首个且目前唯一获批用于靶向治疗HER2高表达胆道癌的产品，领先一个身位。据百济神州官方最新消息，首批泽尼达妥单抗已经在全国百余个城市的医院和药房落地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627210128a4c14cea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627210128a4c14cea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160","BK4526","688235","BK4139"],"gpt_icon":0},{"id":"2546671877","title":"叮噹健康旗下藥房上架百濟神州注射用澤尼達妥單抗(百赫安)","url":"https://stock-news.laohu8.com/highlight/detail?id=2546671877","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546671877?lang=zh_tw&edition=fundamental","pubTime":"2025-06-27 16:48","pubTimestamp":1751014120,"startTime":"0","endTime":"0","summary":"日前, 百济神州双特异性HER2抑制剂百赫安首批药物在叮当健康旗下药房等渠道上架发售,6 月24日,于叮当健康旗下药房正式售出首单。注射用泽尼达妥单抗于2025年5月29日,获附条件批准,用于既往接受过治疗的患者。据了解,叮当健康于2025年持续推进新特药‘生命方舟计划’,在旗下药房全面加强新特药品类布局,已先后上架阿尔茨海默病药品记能达、1类新药注射用瑞康曲妥珠单抗(艾维达)等新特药产品,为提升患者用药可及性带来便利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627165221952ddb11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627165221952ddb11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09886","ONC","688235","06160","BK0239"],"gpt_icon":0},{"id":"2546761985","title":"國產創新藥破曉時刻！華安醫藥軍團以科技思維定義投資新範式","url":"https://stock-news.laohu8.com/highlight/detail?id=2546761985","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546761985?lang=zh_tw&edition=fundamental","pubTime":"2025-06-27 10:20","pubTimestamp":1750990844,"startTime":"0","endTime":"0","summary":"华安医药军团凭借多元化产品矩阵满足不同需求，汇聚产业专家，以科技投资思维构建研究体系。创新药的“破晓时刻”，医药投资的复苏拐点 在国内政策强力扶持、全球竞争力显著提升、出海浪潮集中爆发等多重因素驱动下，2025年，中国创新药行业迎来了属于自己的“破晓时刻”。截至一季度末，华安医药生物持仓包括港股市场和A股市场中多只涨幅明显的创新药个股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627102044a71fcded&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627102044a71fcded&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","688235","688428","BK4139","06160","ONC","BK4526"],"gpt_icon":0},{"id":"1106218367","title":"港股生物醫藥股延續回調，百濟神州跌超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106218367","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106218367?lang=zh_tw&edition=fundamental","pubTime":"2025-06-27 10:13","pubTimestamp":1750990427,"startTime":"0","endTime":"0","summary":"6月27日，港股生物医药股延续回调，百济神州跌超8%，荣昌生物跌超7%，北海康成跌超6%，加科思、中国再生医学、药明巨诺跌超4%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07226","399441","BK1161","LU0588546209.SGD","LU0307460666.USD","BK1588","BK4139","161726","688235","HSCEI","BK4526","LU2328871848.SGD","ONC","BK4614","YANG","BK0239","BK1500","HSTECH","LU1969619763.USD","06160"],"gpt_icon":0},{"id":"2546575067","title":"6 月，恆瑞、百濟神州、復星醫藥等新藥又有新進展，多個關鍵 III 期臨牀啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2546575067","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546575067?lang=zh_tw&edition=fundamental","pubTime":"2025-06-27 07:45","pubTimestamp":1750981540,"startTime":"0","endTime":"0","summary":"III 期临床启动，意味着新药研发已经开始向上市申请发起冲刺。据公开资料，这是该药首次启动 III 期临床。国产方面，三生国健的 SSGJ-611 本次启动 COPD III 期临床。此外，康诺亚/石药集团的司普奇拜单抗已启动 II/III 期，康乃德/先声药业的乐德奇拜单抗正在开展 II 期临床。Insight 数据库显示，在低级别胶质瘤赛道上，国内暂未有相关药物获批上市，芦沃美替尼研发进度位列第一梯队，已开展 III 期关键临床。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627075121a4bfe6d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627075121a4bfe6d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0183","01276","BK0096","BK0175","BK0196","BK0012","600196","BK0060","BK0028","BK0239","600276","BK0187","688235","02196","06160","ONC"],"gpt_icon":0},{"id":"2546780647","title":"解讀全球製藥企業50強榜單：中國創新藥企距離“Big Pharma”還有多遠","url":"https://stock-news.laohu8.com/highlight/detail?id=2546780647","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546780647?lang=zh_tw&edition=fundamental","pubTime":"2025-06-26 20:02","pubTimestamp":1750939355,"startTime":"0","endTime":"0","summary":"近日，美国《制药经理人》杂志发布2025年全球制药企业50强榜单。从产品潜力和研发趋势来看，中国创新药领域的全球化征程已经起航，成为“Big Pharma”只是时间问题。Evaluate Pharma近期发布的最新预测报告表示，到2030年，GLP-1激动剂及相关复方制剂将占所有处方药销售额的近9%。中国药企在前沿疗法“唱主角”上述榜单显示，今年有6家中国企业上榜，数量创近5年新高，但排名均在30名以后。但中国创新药近年来取得的进步有目共睹。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626200338a4bf27b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626200338a4bf27b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","688235","NVO","159992","BK0239","06160","MRK"],"gpt_icon":0},{"id":"2546978975","title":"百濟神州在研發日展示開創性腫瘤治療管線","url":"https://stock-news.laohu8.com/highlight/detail?id=2546978975","media":"百济神州","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546978975?lang=zh_tw&edition=fundamental","pubTime":"2025-06-26 18:07","pubTimestamp":1750932471,"startTime":"0","endTime":"0","summary":"在百济神州，我们的使命明确且坚定——致力于成为推动全球新一代肿瘤治疗创新的先行者。如今，百济神州汇集了超过1200名科学家和3700多名临床开发及医学事务的专业人才，共同致力于推动肿瘤治疗领域的持续突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626182027a4beffdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626182027a4beffdf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0329678170.USD","ONC","BK1583","LU2328871848.SGD","LU0588546209.SGD","BK1588","LU0737861772.HKD","LU0329678337.USD","688235","LU0307460666.USD","LU2488822045.USD","BK1161","BK1500","06078","06160","BK1209","LU1969619763.USD"],"gpt_icon":0},{"id":"2546278232","title":"醫藥估值重估邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2546278232","media":"资本市场那些事儿","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546278232?lang=zh_tw&edition=fundamental","pubTime":"2025-06-26 09:14","pubTimestamp":1750900469,"startTime":"0","endTime":"0","summary":"为什么我会提出这个概念，因为2025，有了一些新变化，对比以往的医药行业，估值的重估，开始一步步的被证实了。——海外大佬来“抢货”大药企“囤货式采购”：2025年起，辉瑞、默沙东等国际巨头疯狂抢购中国创新药管线，尤其是早期项目。叠加大药企的专利陆续到期，都到中国来扫货了。2024年32家药企研发投入672亿，35%砸向早期项目。药企猛冲研发，CXO躺赚订单，技术平台型药企和CXO公司都能迎来一波估值重估。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626092555a4be36c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626092555a4be36c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK4526","06160","ONC","BK4139","01530","09926"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":6,"totalSize":164,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盤前","dateTimestamp":1756526400000,"actualEps":null},{"date":"2025-08-06","symbol":"ONC","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":0.48,"defaultRemindTime":1754467200000,"name":null,"time":"","dateTimestamp":1754452800000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盤前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.6364,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":22,"updateTime":1748318400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-07-29","current":-89.058804,"percent":0.017123,"low":-89.808695,"twenty":-49.066613,"median":-39.846019,"eighty":-23.213907,"high":-19.234246,"avg":-41.413887,"sd":19.655313,"marketCap":34943646841},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575},{"date":"2025-07-29","current":-89.058804,"twenty":-49.066613,"median":-39.846019,"eighty":-23.213907,"marketCap":34943646841}],"updateTime":1753913442723}}}